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Abstract: The misuse of opioids, including codeine which is sold over-the-counter (OTC) in United
Kingdom (UK) community pharmacies, is a growing public health concern. An educational Patient
Safety Card was developed and piloted to see if it nudged customers into the safe and appropriate
use of OTC codeine. Exploratory analysis was conducted by (i) recording quantitative interactions
for people requesting OTC codeine in community pharmacies; and (ii) a web-based pharmacy staff
survey. Twenty-four pharmacies submitted data on 3993 interactions using the Patient Safety Card.
Staff found the majority of interactions (91.3%) to be very or quite easy. Following an interaction
using the card, customers known to pharmacy staff as frequent purchasers of OTC codeine were
more likely not to purchase a pain relief medicine compared to customers not known to staff (5.5%
of known customers did not purchase any pain relief product versus 1.1% for unknown customers
(χ2 = 41.73, df = 1, p < 0.001)). These results support both the use of a visual educational intervention
to encourage appropriate use of OTC codeine in community pharmacy and the principles behind
better self-care.
Keywords: behavioural nudge; codeine; community pharmacy; opioid misuse; over-the-counter
1. Introduction
Opioid analgesics are used for pain relief where medicines such as paracetamol or ibuprofen alone
have not provided relief [1]. In addition to being available on prescription in the UK, codeine-containing
medicines are available to purchase from a pharmacy (usually behind the counter or in locked
cabinets), sold by or under the supervision of a pharmacist, and are known by the metonymic term of
over-the-counter (OTC). The total sales of all codeine-containing OTC products in the United Kingdom
were 26 million units, or 7.8% of the total adult oral pain relief market [2].
Derived from the opium poppy, side effects of codeine consumption include drowsiness, respiratory
depression and also psychoactive effects, such as feelings of euphoria and intoxication [3]. Codeine is
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available in co-formulations, including with paracetamol and ibuprofen, which have been associated
with serious clinical complications such as life-threatening gastrointestinal bleeding and critical
hypokalemia [4]. For children, while codeine is licensed for use in those aged over 12 years in the UK,
it is contraindicated in those under 18 years who have breathing problems [5]. Regular or excessive
use of codeine, even for short periods, can lead to tolerance [6], and psychological and physical
dependence [5]. Those that become dependent may experience negative personal, professional or
social impacts, and obtain illicit supplies; this could lead to criminality and has been linked into several
preventable deaths [7–9]. Although OTC medicines abuse is an internationally recognized problem [10],
the extent of codeine misuse is unclear due to the limited availability of data. One report on pharmacist
perceptions indicated a perceived increase in misuse [11], and another cross-sectional survey of the
general population reported that the products most commonly misused were codeine-containing
analgesics [12].
The ubiquitous nature of OTC medicines enables consumers to take responsibility for their
own health, offers convenience and choice, and reduces the burden on the health service (National
Health Service, NHS) with its associated cost to taxpayers [13,14]. Availability of OTC medicines
may result in a public perception of product safety, although there is conflicting evidence about
individuals’ knowledge of possible harm and risks specifically in relation to medicines that could be
misused [15–17]. Some individuals may unintentionally misuse codeine, for example, by taking it for
longer than recommended (maximum of three days, maximum daily dose 240 mg) [18]. To compound
the issue, there are multiple sources of information which individuals can consult and bypass healthcare
professionals, for example on the internet [7,19]. In addition, patient information leaflets supplied
with medicines can be complex and are often not consulted by consumers [15]. Leaflets also rely on
the individual’s health literacy for comprehension, although poor health literacy is widespread and
directly contributes to health inequalities [20,21].
In 2009, the Medicines and Healthcare products Regulatory Agency implemented new measures
to minimize the risk of harm from OTC codeine (including reducing OTC codeine’s licensed indications,
improving labelling (‘can cause addiction’ and ‘for three days use only’ to be prominently displayed
on the pack) and limiting the pack size to 32 tablets) [22]. There is no legal limit on the sale of
codeine-containing medicines, either in one transaction or over a set time period; however, the Royal
Pharmaceutical Society recommends that only one pack of codeine- or dihydrocodeine-containing
medication should be sold [23]. In 2018, Australia joined 25 other countries including Germany, Japan
and the US in restricting codeine to prescription-only due to the health risks it posed [24–26]. This change
has received mixed responses from pharmacists regarding their ability to support consumers with
pain management, although it appears to have helped reduce codeine misuse [27,28].
In the UK, despite evidence supporting its use for short-term and self-limiting conditions [5],
the limited evidence supporting analgesic benefit from codeine [29] means that misuse concerns remain.
Reclassification of OTC codeine could become burdensome for the NHS, goes against NHS policy of
promoting self-care [30], is likely to be met with resistance from manufacturers [14], and may result in
codeine being sourced illicitly [31]. Some experts argue that an appropriate and enhanced intervention,
at an early stage in community pharmacy, is preferable [26].
Pharmacists have a professional duty to support individuals’ health decisions [32] and could
be more proactive when facing potential misuse [18,33,34]. Pharmacists are well placed to support
consumers with responsible decision-making regarding medication [35], despite frequently cited
barriers of resource and capacity constraints [36]. Provision of advice has been shown to support the
selection of the most safe and effective product [37], improve health outcomes, and positively impact
quality of life [38]. There is, however, evidence that appropriate advice is not always provided and can
be of variable quality [39–41].
For OTC codeine, behavioral change techniques could be particularly effective for consumers
more focused on the current benefit of analgesia, without consideration of the potential consequences
from misuse [42]. According to Thaler and Sunstain, consumers who consider the ‘benefits now’ and
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‘costs later’ can be ‘nudged’ into altering their behavior [43]. Incorporation of an educational nudge
could be one method to improve responsible patient usage of OTC codeine. Therefore, a ‘Patient
Safety Card’ was developed based on the framework that capability, opportunity and motivation can
impact on behavior (‘COM-B’) [44]. The card was designed for community pharmacy staff to use with
purchasers of OTC codeine medicines to reinforce and encourage its safe and appropriate use.
The aim of this evaluation was to pilot the card in pharmacies to see if it supported pharmacy
teams’ interactions with consumers to influence (i.e., nudge) behavior towards the safe and appropriate
use of OTC codeine. The objectives of this work were to: (1) test the ease with which pharmacy
teams felt able to encourage the safe and appropriate use of OTC codeine by using the card alongside
the normal provision of advice (in both known and unknown customers); (2) understand the views
of pharmacy teams on customers’ receptiveness to the card; (3) assess if provision of the card led
to an alternative outcome to the customer’s intended OTC codeine purchase; (4) explore the views
and experiences of pharmacy teams on use of the card and any improvements that could be made
to its format and design; and (5) solicit views on potential risk minimization measures relating to
OTC codeine.
2. Materials and Methods
Using the principals of the Antimicrobial Resistance checklist [45] as a basis for the intervention,
and the five clinical points considered key to the safe and appropriate use of OTC codeine [5], a panel
of experts (including regulatory experts and community pharmacists with experience selling these
medicines OTC) discussed and developed the final messages. As a result, an A6-sized card (Figure S1)
was developed and distributed to 36 community pharmacies across a national chain (Boots UK).
Pharmacies were purposefully selected based on the highest volume of OTC codeine sales, including a
range of pharmacy formats (high street, local community and shopping centers), geographical spread
and taking into account Covid-19′s operational impact.
The card was handed over to the patient by the pharmacy team member supporting the interaction
(pharmacy advisor, pharmacy technician or pharmacist). It was used in addition to the pharmacy chain’s
healthcare consultation model, which focusses on ensuring safe and appropriate sales, and empowering
patient choice through a holistic, advice-led approach. After a suitability assessment, the consultation
model supports provision of advice using the CARE framework (Counsel; Avoid; Read; Escalate).
This framework includes counselling on how to take medication, any reason the medication should be
avoided, a reminder to read the patient information leaflet, and advice for escalation actions if symptoms
remain unresolved (safety netting). Codeine is also highlighted on a list of ‘people and products’ to
take extra care with during an interaction, which complements the healthcare consultation model.
Pharmacy staff were asked to complete a paper copy of a data entry ‘tracker’ after each OTC codeine
product request where the card was used over a five week period in June and July 2020 (Figure S2).
Pharmacies were told to include transactions for codeine-containing medicines, including codeine and
dihydrocodeine. The main fields recorded were (i) staff ease of use of the card; (ii) receptiveness of
customer to the card; (iii) outcome of customer consultation; and (iv) an annotation where the customer
was familiar to staff as a frequent purchaser of OTC codeine in that pharmacy (“known customer”).
Data were collected (via electronic photos of the paper copies being sent to Boots head office staff),
inputted and descriptive analysis performed using Microsoft Excel 365 version 16.37, and a chi squared
test for association. Associations between receptiveness and ease of use and whether there were any
differences in outcomes between known and unknown customers were explored.
A pharmacy staff survey was used to collect insights into experience of card use to see if it
supported perceived behavioral change with customers, and solicit views on the wider management
of OTC codeine (Table S1). The survey was piloted on a small number of colleagues before finalizing
the questions for use with participants. All pharmacy staff involved in using the card were invited
to complete the pseudonymized online survey over a one week period after the pilot had begun.
Invitations to participate were sent via the internal communications channels to all participating
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pharmacies. Data were manually coded to explore themes based on the questions posed using thematic
analysis, and the COM-B framework [44]. The COM-B model proposes that a combination of the
following impacts on behavior (B): C: capability (the individual’s physical and psychological ability,
including their skill and knowledge); O: opportunity (external social or physical contextual factors);
and M: motivation (an individual’s automatic and reflective processes, for example, their habits, choices
and beliefs). By analyzing the three determinants of behavior, possible intervention functions based on
Michie’s Behaviour Change Wheel can then be linked to specific behavioral change techniques (i.e.,
a ‘nudge’) [44]. An educational intervention suits circumstances where capability and motivation can
be changed, and has been shown to be highly successful [46,47].
Approval for the service evaluation was obtained from Nottingham Business School, Nottingham
Trent University (as analysis was completed as part of an MBA study), and Boots’ Research
Governance Board.
3. Results
Of the 36 pharmacies involved in the project, 3993 complete tracker entries were received from
24 pharmacies. For these 24 pharmacies, there was a mean of 166 responses per pharmacy; range
8 to 480 overall responses per pharmacy; mean 10.9 responses per pharmacy per day, range 0 to
48 responses per pharmacy per day). Survey responses were received from 23 pharmacy staff across
22 pharmacies (10 pharmacists; 3 pharmacist store managers; 2 store managers; 4 manager assistants;
2 pre-registration pharmacists; 1 pharmacy advisor; and 1 pharmacy technician). Datasets are available
in the Supplementary Material.
3.1. Tracker Data
Pharmacy staff considered the vast majority of conversations (91.3%, n = 3644) to be very or
quite easy, and, of these, the majority of customers (83.4%, n = 3040) were reported to be receptive.
Where pharmacy staff found the conversation difficult (n = 349), 90.0% of customers were not receptive
or refused the card.
Known customers were observed to account for 8.7% (n = 347) of tracked interactions (Table 1).
Pharmacy staff found 90.2% (n = 313) of conversations with known customers and 91.4% (n = 3331)
of unknown customers to be easy. In terms of customer receptiveness, 72.9% (n = 253) of known
customers and 77.4% (n = 2822) of unknown customers were perceived by the pharmacy staff to be
receptive (χ2 = 3.61, df = 1, p = 0.06). Known customers refused the card in 11.0% (n = 38) of cases,
compared to 6.6% (n = 239) of unknown customers (χ2 = 9.48, df = 1, p = 0.002).
Table 1. Ease/difficulty of conversation and perceived receptiveness of known and unknown customers
(Note: each table adds up to 100% to show distribution across cells).
Known Customers (n = 347)
Receptiveness
Ease/Difficulty
Very easy Quite easy Quite difficult Very difficult
Refused the card 5.2% 1.1% 1.4% 3.2%
Not receptive 7.8% 3.2% 4.0% 1.2%
Quite receptive 19.0% 7.2% 0.0% 0.0%
Very receptive 45.0% 1.7% 0.0% 0.0%
Unknown Customers (n = 3646)
Receptiveness
Ease/Difficulty
Very easy Quite easy Quite difficult Very difficult
Refused the card 1.1% 2.5% 1.8% 1.1%
Not receptive 5.5% 5.8% 4.3% 0.5%
Quite receptive 17.8% 14.2% 0.9% 0.0%
Very receptive 42.4% 2.0% 0.1% 0.0%
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The vast majority of customers (97.4%, n = 3891) purchased the originally intended OTC codeine
product (Table 2); 94.5% (n = 328) for known customers and 97.7% (n = 3563) for unknown customers
(χ2 = 13.03, df = 1, p < 0.001). Furthermore, 5.5% (n = 19) of known customers did not purchase any
pain relief product, which was different to unknown customers at 1.1% (n = 40) (χ2 = 41.73, df = 1,
p < 0.001).
Table 2. Outcomes of interactions using the card.





Original codeine product purchased 97.7% 94.5% 97.4%
Smaller pack of codeine product purchased 0.6% 0.0% 0.5%
Non-codeine product purchased 0.6% 0.0% 0.6%
No product purchased 1.0% 5.2% 1.4%
No product purchased and customer
signposted 0.1% 0.3% 0.1%
3.2. Staff Survey
All pharmacy staff (pharmacists and healthcare staff) that responded to the survey reported
using the card to support their conversations with customers when purchasing OTC codeine products.
An overarching theme was that the card helped to reiterate the key risks associated with the use
of OTC codeine with 91.3% (n = 21) of survey respondents saying it supported their conversations.
All respondents replied yes (47.8%, n = 11) or maybe (52.2%, n = 12) when asked if they would
recommend using the card to other pharmacy teams and a number commented that the messaging
conveyed the key risks in a clearer and more readable way than the packaging or patient information
leaflet. Another key theme was that customers were able to take the card away to read, review, refer to
and reflect on at a later stage. Only a third of respondents (34.8%, n = 8) considered that the card would
help achieve the most appropriate outcome for the customer. This appeared to be based on the fact that
customers often requested codeine by name and, as noted previously, the vast majority of customers
(97.4%, n = 3891) went on to purchase the originally intended codeine product. Around two-thirds of
respondents were keen to receive further professional (n = 15) and clinical (n = 14) training to help
better support customers in their use of OTC codeine.
Improved patient knowledge was reflected in the identification of risk minimization options;
78.3% of respondents (n = 18) supported a patient education and awareness campaign and 65.2%
(n = 15) supported the cessation of promotional activity and advertising of OTC codeine. Only 47.8%
(n = 11) supported a switch (upschedule) of codeine to a Prescription-Only Medicine.
4. Discussion
These results demonstrate that ease of utilizing the card was linked to the staff-perceived
receptiveness of each customer. Despite the differing levels of customer engagement, this supports
previous research [48] that some consumers will be seeking advice from pharmacy teams. With the
majority of interactions using the card classed as easy and with receptive customers, this work indicates
that pharmacy teams can influence an individual’s knowledge and comprehension about the safe and
appropriate use of OTC codeine. Due to the variable skills and expertise of pharmacy teams previously
identified [41], the requirement for training to enhance the interactions remains [7].
Although the level of ease seemed related to the receptiveness, it is not possible to determine
from the data if one precedes the other, i.e., if an easy conversation leads to a receptive customer
or whether it is the receptiveness of the customer that determines the ease. Furthermore, staff may
have categorized the ease and the receptiveness differently based on their own ability (particularly
with respect to the subjective nature of perceived ‘receptiveness’) and their perception may have been
altered by, for example, familiarity with customers or language barriers. This may provide some
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explanation as to why some conversations deemed very easy still resulted in the customer being
perceived as unreceptive or refusing the card. Further work to understand this could be considered
with more robust operationalization of the idea of receptiveness.
Advertising of OTC codeine is considered to add weight to the perception of safety and efficacy,
and could result in customers seeking to purchase the product [49] even where staff consider it may
not be the most appropriate treatment. Given cessation of advertising was ranked high as a risk
minimization option in the survey, it is apparent that pharmacy teams wish to persist in their role
as the prime source of advice for consumers on use of OTC medicines and be able to influence their
health choices.
Despite other research showing that previously used medication and medicines advice can support
appropriate product selection [37], staff remained of the view that the most appropriate outcome was
only achieved in around one third of interactions. Coupled with tracker data showing that the vast
majority of customers continued with their intended purchase, this validates previous research that
customers seeking OTC codeine can be better supported [7,50]. This type of interaction with pharmacy
staff provides potential opportunities for early intervention where pain management and the use of
opioids is concerned; reinforcing appropriate use and helping to reduce ‘gateway’ risk. It further
supports the principles of joint decision-making and patient empowerment.
The most appropriate outcome is, however, subjective and based on judgement, particularly
in the absence of a formalized clinical relationship between the pharmacy team and the consumer.
Nonetheless, these results do show that the card appeared to influence the outcome for some
customers and, combined with the survey responses noting how it would encourage customers to
consciously consider their choices, this reveals that the card impacted customers’ reflective motivation.
This reflective motivation could then have been mediated by the information on the card, with key
risks presented in a novel way, affecting customers’ psychological capability.
Staff were keen to recommend the card to colleagues and see enhanced patient education and
awareness in relation to OTC codeine although this assumes customers do not already have the requisite
knowledge. The heterogeneous intentions of customers with regards to seeking medicines advice [51,52]
does, however, reinforce the role of community pharmacy in fulfilling those needs [48], particularly as
customers can opt to purchase OTC codeine online thereby avoiding a face to face interaction.
A small proportion of customers were immediately nudged into an alternative outcome and,
despite not being observable during the trial period, it is possible that the impact of the nudge
affected additional customers at a later stage, once they had an opportunity to absorb the card
information [36,53]. The results also reveal two important behavioral changes for known customers,
where the purchase of OTC codeine may have become habitualized. First, known customers were more
likely to refuse the card and, second, they were more likely not to make a purchase for a pain relief
medicine following intervention with the card. This demonstrates that the card disrupted the normal
course of their behavior. One explanation is that the customer responded to the card, but equally
they could have felt embarrassed or stigmatized with the interaction, or have chosen to purchase
OTC codeine elsewhere. The effect observed could have been greater as identification of 8.7% of
customers as known customers is considered to be an understatement of the reality based on previous
research [15,17]. This may be due to staff being unwilling to categorize customers in this way, lack of
awareness, or a reluctance to admit that previous counselling efforts have been ineffective as witnessed
by others [41]. It is also possible that Covid-19, given its significant impact on reducing the overall
number of customers attending pharmacies, may have distorted the known customer proportion and
may have also caused wider variation in transactions for each pharmacy than may have been expected.
This, along with the high pressures faced by pharmacies during this time, is also likely to have been
the cause of a proportion of pharmacies not returning any data.
The benefit to unknown customers can also be seen by their perceived receptiveness to the card.
For these customers, the card can deliver an early intervention into codeine use, and potentially amend
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future behavior when it comes to purchasing OTC codeine [26]. It also provides an opportunity to
signpost and refer those needing additional help onto other more appropriate services.
The main limitations of this study design are that it is not possible to compare the data to
a baseline as the potential outcome without use of the card is not known, nor is the number of
customers purchasing OTC codeine during the data collection period known. In addition, without
access to medical history, or a robust referral mechanism to an alternative healthcare provider or
service, the ability of pharmacy teams to provide comprehensive care is limited. Although these
results indicate that 10% of interactions were with known customers and this may raise concerns
regarding their care, it is not clear whether this is an accurate estimate of this population. There are a
number of caveats that need to be considered when contemplating this. For example, staff turnover,
shift patterns and use of locum workers will all impact the consistency of staff a customer may deal
with and Covid-19 may have impacted the types and mix of customers presenting in the pharmacy.
In addition, it was not the objective of this study to quantify the percentage of known customers, but to
understand their receptiveness to the support, therefore the method of tracking was not designed to
do this robustly. This does highlight that the needs of these customers may be different to others and
that community pharmacy should be able to identify these customers and direct them to specialist
services. These limitations could be addressed in further research. Despite these limitations, given the
exploratory nature of the project, the geographical spread and high number of interactions recorded,
these results still provide key insights into understanding how an educational intervention could be
used in community pharmacy to nudge consumer behavior.
5. Conclusions
The findings indicate that the card was considered by staff to be easy to use and a useful prompt
to support discussions with customers on appropriate and safe use of codeine-containing medicines.
It enhanced the information provided during normal medicines counselling, was perceived as being
generally well-received by customers and, in particular, supported conversations with customers that
were known to the pharmacy staff (resulting in a higher proportion of these customers having an
outcome which differed to the originally intended purchase). These results demonstrate the value
community pharmacy can bring by being able to change consumers’ behavior and that this can be
delivered with a physical, visual, low-cost product to augment the verbal advice and counselling
currently provided. If implemented sector-wide, the behavioral change effect could be even more
marked. With staff training to boost confidence and moral courage to tackle misuse, the card can
add to public awareness of the risks associated with codeine and support retention of codeine as an
OTC medicine.
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